In addition, new avenues have recently been explored focusing on inhibitory peptides that either induce the cytotoxic anti-cancer activity of CTLs or mimic key interacting domains on CD138, as well as polymers that offer the possibility of disrupting molecular interactions useful for MM progression leading to anti-cancer activity. Here, SDC1 is linked to Miyoshi myopathy.